Unveiling 6 Analyst Insights On Capricor Therapeutics
Capricor Therapeutics Analyst Ratings
H.C. Wainwright Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $40
Capricor Therapeutics' CAP-1002 Shows Promise in DMD Treatment: Buy Rating Affirmed Following Positive Clinical Trials
Capricor Therapeutics Set to Join Russell 2000 and Russell 3000 Indexes
Capricor Therapeutics (CAPR) Gets a Buy From Oppenheimer
What's Going On With Capricor Therapeutics Stock Friday?
Capricor Therapeutics Rises on Muscular Dystrophy Treatment Study
Express News | Capricor Therapeutics Inc: Pre-Bla Meeting With FDA Scheduled for Q3 2024 to Discuss Options to Expedite Bla Filing
Express News | Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (Cap-1002) in Both Skeletal Muscle and Cardiac Function in the Hope-2 Ole Study in Duchenne Muscular Dystrophy
Express News | Corrected(Official)-Capricor Therapeutics Announces Pre-Bla Meeting With FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy (Adds Dropped Words 'pre-Bla Meeting With FDA for Deramiocel')
CORRECTION: Capricor Therapeutics
Express News | Capricor Therapeutics Inc: FDA Scheduled Pre-Bla Meeting in Q3 for Deramiocel (Cap-1002)
Express News | Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
Oppenheimer Maintains Capricor Therapeutics(CAPR.US) With Buy Rating, Maintains Target Price $14
Express News | Capricor Therapeutics Files For Mixed Shelf Offering Of Up To $150M
Express News | Capricor Therapeutics Inc Files for Mixed Shelf Offering of up to $150 Mln- SEC Filing
12 Health Care Stocks Moving In Tuesday's After-Market Session
Sector Update: Health Care Stocks Decline Tuesday Afternoon
Capricor Says FDA Grants Pre-BLA Meeting Request for Duchenne Muscular Dystrophy Treatment; Shares Rise